By HANNAH RECHT <a href="https://dailymontanan.com/2022/12/12/paxlovid-has-been-free-now-comes-the-sticker-shock/">Kaiser Health News, courtesy Daily Montanan</a>

Nearly 6 million Americans have taken Paxlovid for free, courtesy of 
the federal government. The Pfizer pill has helped prevent many people 
infected with COVID-19 from <a target="_blank" href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7148e2.htm">being hospitalized</a> or dying, and it may even <a target="_blank" href="https://www.medrxiv.org/content/10.1101/2022.11.03.22281783v1">reduce the risk</a>
 of developing long COVID. But the government plans to stop footing the 
bill within months, and millions of people who are at the highest risk 
of severe illness and are least able to afford the drug — the uninsured 
and seniors — may have to pay the full price.

And that means fewer people will get the potentially lifesaving treatments, experts said.

“I think the numbers will go way down,” said Jill Rosenthal, director
 of public health policy at the Center for American Progress, a 
left-leaning think tank. A bill for several hundred dollars or more 
would lead many people to decide the medication isn’t worth the price, 
she said.

In response to the unprecedented public health crisis caused by 
COVID, the federal government spent billions of dollars on developing 
new vaccines and treatments, to swift success: Less than a year after 
the pandemic was declared, medical workers got their first vaccines. But
 as many people have refused the shots and stopped wearing masks, the 
virus still rages and mutates. In 2022 alone, 250,000 Americans <a target="_blank" href="https://covid.cdc.gov/covid-data-tracker/#trends_totaldeaths_select_00">have died</a> from COVID, <a target="_blank" href="https://data.cdc.gov/NCHS/Monthly-Provisional-Counts-of-Deaths-by-Select-Cau/9dzk-mvmi/data">more than</a> from strokes or diabetes.

But soon the Department of Health and Human Services will stop 
supplying COVID treatments, and pharmacies will purchase and bill for 
them the same way they do for antibiotic pills or asthma inhalers. 
Paxlovid is expected to hit the private market in mid-2023, according to
 HHS plans shared in an October meeting with state health officials and 
clinicians. Merck’s Lagevrio, a less-effective COVID treatment pill, and
 AstraZeneca’s Evusheld, a preventive therapy for the immunocompromised,
 are on track to be commercialized sooner, sometime in the winter.

The U.S. government has so far purchased <a target="_blank" href="https://www.whitehouse.gov/briefing-room/statements-releases/2022/04/26/fact-sheet-biden-administration-increases-access-to-covid-19-treatments-and-boosts-patient-and-provider-awareness/">20 million courses</a>
 of Paxlovid, priced at about $530 each, a discount for buying in bulk 
that Pfizer CEO Albert Bourla called “really very attractive” to the 
federal government in a July earnings call. The drug will cost far more 
on the private market, although in a statement to KHN, Pfizer declined 
to share the planned price. The government will also stop paying for the
 company’s COVID vaccine next year — those shots will <a target="_blank" href="https://khn.org/news/article/pfizer-covid-cash-marketing-drugs/">quadruple in price</a>, from the discount rate the government pays of $30 to about $120.

Bourla told investors in November that he expects the move will make 
Paxlovid and its COVID vaccine “a multibillion-dollars franchise.”

Nearly <a target="_blank" href="https://www.washingtonpost.com/health/2022/11/28/covid-who-is-dying/">9 in 10 people</a> dying from the virus now are 65 or older. Yet federal law restricts Medicare Part D — the prescription drug program that <a target="_blank" href="https://www.kff.org/other/state-indicator/medicare-beneficiaries-enrolled-in-part-d-coverage/?currentTimeframe=0&amp;sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D">covers nearly 50 million seniors</a>
 — from covering the COVID treatment pills. The medications are meant 
for those most at risk of serious illness, including seniors.

Paxlovid and the other treatments are currently available under an 
emergency use authorization from the FDA, a fast-track review used in 
extraordinary situations. Although Pfizer <a target="_blank" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda">applied for full approval</a>
 in June, the process can take anywhere from several months to years. 
And Medicare Part D can’t cover any medications without that full stamp 
of approval.

Paying out-of-pocket would be “a substantial barrier” for seniors on 
Medicare — the very people who would benefit most from the drug, wrote <a target="_blank" href="https://aspe.hhs.gov/sites/default/files/documents/1072f5093254224ac902ca395387085c/coverage-considerations-covid-19.pdf">federal health experts</a>.

“From a public health perspective, and even from a health care 
capacity and cost perspective, it would just defy reason to not continue
 to make these drugs readily available,” said Dr. Larry Madoff, medical 
director of Massachusetts’ Bureau of Infectious Disease and Laboratory 
Sciences. He’s hopeful that the federal health agency will find a way to
 set aside unused doses for seniors and people without insurance.

In mid-November, the White House requested that Congress approve an 
additional $2.5 billion for COVID therapeutics and vaccines to make sure
 people can afford the medications when they’re no longer free. But 
there’s little hope it will be approved — the Senate <a target="_blank" href="https://www.wsj.com/articles/senate-votes-to-end-covid-19-emergency-declaration-11668559887">voted that same day to end</a> the public health emergency and denied similar requests in recent months.

Many Americans have already faced hurdles just <a target="_blank" href="https://khn.org/news/article/test-to-treat-biden-covid-failing-patients-pharmacies-cvs/">getting a prescription</a> for COVID treatment. Although the federal government <a target="_blank" href="https://khn.org/news/article/paxlovid-covid-pill-antiviral-access-data/">doesn’t track</a> who’s gotten the drug, a <a target="_blank" href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7143a2.htm">Centers for Disease Control and Prevention study</a>
 using data from 30 medical centers found that Black and Hispanic 
patients with COVID were much less likely to receive Paxlovid than white
 patients. (Hispanic people can be of any race or combination of races.)
 And when the government is no longer picking up the tab, experts 
predict that these gaps by race, income, and geography will widen.

People in Northeastern states used the drug far more often than those
 in the rest of the country, according to a Kaiser Health News analysis 
of Paxlovid use in September and October. But it wasn’t because people 
in the region were getting sick from COVID at much higher rates — 
instead, many of those states offered better <a target="_blank" href="https://www.cdc.gov/nchs/hus/report.htm">access to health care</a> to begin with and created special programs to get Paxlovid to their residents.

About 10 mostly Democratic states and several large counties in the 
Northeast and elsewhere created free “test-to-treat” programs that allow
 their residents to get an immediate doctor visit and prescription for 
treatment after testing positive for COVID. In Massachusetts, more than 
20,000 residents have used the state’s <a target="_blank" href="https://www.mass.gov/info-details/free-telehealth-for-covid-19-treatment-with-paxlovid">video and phone hotline</a>,
 which is available seven days a week in 13 languages. Massachusetts, 
which has the highest insurance rate in the country and relatively low 
travel times to pharmacies, had the second-highest Paxlovid usage rate 
among states this fall.

States with higher COVID death rates, like Florida and Kentucky, 
where residents must travel farther for health care and are more likely 
to be uninsured, used the drug less often. Without no-cost test-to-treat
 options, <a target="_blank" href="https://khn.org/news/article/test-to-treat-biden-covid-failing-patients-pharmacies-cvs/">residents have struggled</a> to get prescriptions even though the drug itself is still free.

“If you look at access to medications for people who are uninsured, I
 think that there’s no question that will widen those disparities,” 
Rosenthal said.

People who get insurance through their jobs could face high copays at
 the register, too, just as they do for insulin and other expensive or 
brand-name drugs.

Most private insurance companies will end up covering COVID 
therapeutics to some extent, said Sabrina Corlette, a research professor
 at Georgetown University’s Center on Health Insurance Reforms. After 
all, the pills are cheaper than a hospital stay. But for most people who
 get insurance through their jobs, there are “really no rules at all,” 
she said. Some insurers could take months to add the drugs to their 
plans or decide not to pay for them.

And the additional cost means many people will go without the medication.

“We know from lots of research that when people face cost sharing for
 these drugs that they need to take, they will often forgo or cut back,”
 Corlette said.

One group doesn’t need to worry about sticker shock. Medicaid, the 
public insurance program for low-income adults and children, will cover 
the treatments in full until at least early 2024.

HHS officials could set aside any leftover taxpayer-funded medication
 for people who can’t afford to pay the full cost, but they haven’t 
shared any concrete plans to do so. The government purchased 20 million 
courses of Paxlovid and 3 million of Lagevrio. Fewer than a third have 
been used, and usage has fallen in recent months, according to KHN’s 
analysis of the data from HHS.

Sixty percent of the government’s supply of Evusheld is also still available, although the COVID prevention therapy is <a target="_blank" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld">less effective</a> against new strains of the virus. The health department in one state, <a target="_blank" href="https://files.constantcontact.com/8088728e101/558b11b0-e00f-47d7-8ec1-645904ec1905.pdf">New Mexico</a>, has recommended against using it.

HHS did not make officials available for an interview or answer written questions about the commercialization plans.

The government created a potential workaround when they moved 
bebtelovimab, another COVID treatment, to the private market this 
summer. It now retails for $2,100 per patient. The agency set aside the 
remaining 60,000 government-purchased doses that hospitals could use to 
treat uninsured patients in a convoluted <a target="_blank" href="https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Bebtelovimab/Pages/default.aspx">dose-replacement process</a>. But it’s hard to tell how well that setup would work for Paxlovid: Bebtelovimab was already much less popular, and the FDA <a target="_blank" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region">halted its use</a> on Nov. 30 because it’s less effective against current strains of the virus.

Federal officials and insurance companies would have good reason to 
make sure patients can continue to afford covid drugs: They’re far 
cheaper than if patients land in the emergency room.

“The medications are so worthwhile,” said Madoff, the Massachusetts 
health official. “They’re not expensive in the grand scheme of health 
care costs.”

<a target="_blank" href="https://www.khn.org/about-us">KHN</a> 
(Kaiser Health News) is a national newsroom that produces in-depth 
journalism about health issues. Together with Policy Analysis and 
Polling, KHN is one of the three major operating programs at <a target="_blank" href="https://www.kff.org/about-us">KFF</a> (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

<figure>
 <img src="https://media.eaglewebservices.com/public/2022/12/1670875530434.png" alt="CDC image" />
 <figcaption>CDC image</figcaption>
 </figure>By HANNAH RECHT <a href="https://dailymontanan.com/2022/12/12/paxlovid-has-been-free-now-comes-the-sticker-shock/">Kaiser Health News, courtesy Daily Montanan</a>Nearly 6 million Americans have taken Paxlovid for free, courtesy of 
the federal government. The Pfizer pill has helped prevent many people 
infected with COVID-19 from <a target="_blank" href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7148e2.htm">being hospitalized</a> or dying, and it may even <a target="_blank" href="https://www.medrxiv.org/content/10.1101/2022.11.03.22281783v1">reduce the risk</a>
 of developing long COVID. But the government plans to stop footing the 
bill within months, and millions of people who are at the highest risk 
of severe illness and are least able to afford the drug — the uninsured 
and seniors — may have to pay the full price.And that means fewer people will get the potentially lifesaving treatments, experts said.“I think the numbers will go way down,” said Jill Rosenthal, director
 of public health policy at the Center for American Progress, a 
left-leaning think tank. A bill for several hundred dollars or more 
would lead many people to decide the medication isn’t worth the price, 
she said.In response to the unprecedented public health crisis caused by 
COVID, the federal government spent billions of dollars on developing 
new vaccines and treatments, to swift success: Less than a year after 
the pandemic was declared, medical workers got their first vaccines. But
 as many people have refused the shots and stopped wearing masks, the 
virus still rages and mutates. In 2022 alone, 250,000 Americans <a target="_blank" href="https://covid.cdc.gov/covid-data-tracker/#trends_totaldeaths_select_00">have died</a> from COVID, <a target="_blank" href="https://data.cdc.gov/NCHS/Monthly-Provisional-Counts-of-Deaths-by-Select-Cau/9dzk-mvmi/data">more than</a> from strokes or diabetes.But soon the Department of Health and Human Services will stop 
supplying COVID treatments, and pharmacies will purchase and bill for 
them the same way they do for antibiotic pills or asthma inhalers. 
Paxlovid is expected to hit the private market in mid-2023, according to
 HHS plans shared in an October meeting with state health officials and 
clinicians. Merck’s Lagevrio, a less-effective COVID treatment pill, and
 AstraZeneca’s Evusheld, a preventive therapy for the immunocompromised,
 are on track to be commercialized sooner, sometime in the winter.The U.S. government has so far purchased <a target="_blank" href="https://www.whitehouse.gov/briefing-room/statements-releases/2022/04/26/fact-sheet-biden-administration-increases-access-to-covid-19-treatments-and-boosts-patient-and-provider-awareness/">20 million courses</a>
 of Paxlovid, priced at about $530 each, a discount for buying in bulk 
that Pfizer CEO Albert Bourla called “really very attractive” to the 
federal government in a July earnings call. The drug will cost far more 
on the private market, although in a statement to KHN, Pfizer declined 
to share the planned price. The government will also stop paying for the
 company’s COVID vaccine next year — those shots will <a target="_blank" href="https://khn.org/news/article/pfizer-covid-cash-marketing-drugs/">quadruple in price</a>, from the discount rate the government pays of $30 to about $120.Bourla told investors in November that he expects the move will make 
Paxlovid and its COVID vaccine “a multibillion-dollars franchise.”Nearly <a target="_blank" href="https://www.washingtonpost.com/health/2022/11/28/covid-who-is-dying/">9 in 10 people</a> dying from the virus now are 65 or older. Yet federal law restricts Medicare Part D — the prescription drug program that <a target="_blank" href="https://www.kff.org/other/state-indicator/medicare-beneficiaries-enrolled-in-part-d-coverage/?currentTimeframe=0&amp;sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D">covers nearly 50 million seniors</a>
 — from covering the COVID treatment pills. The medications are meant 
for those most at risk of serious illness, including seniors.Paxlovid and the other treatments are currently available under an 
emergency use authorization from the FDA, a fast-track review used in 
extraordinary situations. Although Pfizer <a target="_blank" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda">applied for full approval</a>
 in June, the process can take anywhere from several months to years. 
And Medicare Part D can’t cover any medications without that full stamp 
of approval.Paying out-of-pocket would be “a substantial barrier” for seniors on 
Medicare — the very people who would benefit most from the drug, wrote <a target="_blank" href="https://aspe.hhs.gov/sites/default/files/documents/1072f5093254224ac902ca395387085c/coverage-considerations-covid-19.pdf">federal health experts</a>.“From a public health perspective, and even from a health care 
capacity and cost perspective, it would just defy reason to not continue
 to make these drugs readily available,” said Dr. Larry Madoff, medical 
director of Massachusetts’ Bureau of Infectious Disease and Laboratory 
Sciences. He’s hopeful that the federal health agency will find a way to
 set aside unused doses for seniors and people without insurance.In mid-November, the White House requested that Congress approve an 
additional $2.5 billion for COVID therapeutics and vaccines to make sure
 people can afford the medications when they’re no longer free. But 
there’s little hope it will be approved — the Senate <a target="_blank" href="https://www.wsj.com/articles/senate-votes-to-end-covid-19-emergency-declaration-11668559887">voted that same day to end</a> the public health emergency and denied similar requests in recent months.Many Americans have already faced hurdles just <a target="_blank" href="https://khn.org/news/article/test-to-treat-biden-covid-failing-patients-pharmacies-cvs/">getting a prescription</a> for COVID treatment. Although the federal government <a target="_blank" href="https://khn.org/news/article/paxlovid-covid-pill-antiviral-access-data/">doesn’t track</a> who’s gotten the drug, a <a target="_blank" href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7143a2.htm">Centers for Disease Control and Prevention study</a>
 using data from 30 medical centers found that Black and Hispanic 
patients with COVID were much less likely to receive Paxlovid than white
 patients. (Hispanic people can be of any race or combination of races.)
 And when the government is no longer picking up the tab, experts 
predict that these gaps by race, income, and geography will widen.People in Northeastern states used the drug far more often than those
 in the rest of the country, according to a Kaiser Health News analysis 
of Paxlovid use in September and October. But it wasn’t because people 
in the region were getting sick from COVID at much higher rates — 
instead, many of those states offered better <a target="_blank" href="https://www.cdc.gov/nchs/hus/report.htm">access to health care</a> to begin with and created special programs to get Paxlovid to their residents.About 10 mostly Democratic states and several large counties in the 
Northeast and elsewhere created free “test-to-treat” programs that allow
 their residents to get an immediate doctor visit and prescription for 
treatment after testing positive for COVID. In Massachusetts, more than 
20,000 residents have used the state’s <a target="_blank" href="https://www.mass.gov/info-details/free-telehealth-for-covid-19-treatment-with-paxlovid">video and phone hotline</a>,
 which is available seven days a week in 13 languages. Massachusetts, 
which has the highest insurance rate in the country and relatively low 
travel times to pharmacies, had the second-highest Paxlovid usage rate 
among states this fall.States with higher COVID death rates, like Florida and Kentucky, 
where residents must travel farther for health care and are more likely 
to be uninsured, used the drug less often. Without no-cost test-to-treat
 options, <a target="_blank" href="https://khn.org/news/article/test-to-treat-biden-covid-failing-patients-pharmacies-cvs/">residents have struggled</a> to get prescriptions even though the drug itself is still free.“If you look at access to medications for people who are uninsured, I
 think that there’s no question that will widen those disparities,” 
Rosenthal said.People who get insurance through their jobs could face high copays at
 the register, too, just as they do for insulin and other expensive or 
brand-name drugs.Most private insurance companies will end up covering COVID 
therapeutics to some extent, said Sabrina Corlette, a research professor
 at Georgetown University’s Center on Health Insurance Reforms. After 
all, the pills are cheaper than a hospital stay. But for most people who
 get insurance through their jobs, there are “really no rules at all,” 
she said. Some insurers could take months to add the drugs to their 
plans or decide not to pay for them.And the additional cost means many people will go without the medication.“We know from lots of research that when people face cost sharing for
 these drugs that they need to take, they will often forgo or cut back,”
 Corlette said.One group doesn’t need to worry about sticker shock. Medicaid, the 
public insurance program for low-income adults and children, will cover 
the treatments in full until at least early 2024.HHS officials could set aside any leftover taxpayer-funded medication
 for people who can’t afford to pay the full cost, but they haven’t 
shared any concrete plans to do so. The government purchased 20 million 
courses of Paxlovid and 3 million of Lagevrio. Fewer than a third have 
been used, and usage has fallen in recent months, according to KHN’s 
analysis of the data from HHS.Sixty percent of the government’s supply of Evusheld is also still available, although the COVID prevention therapy is <a target="_blank" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld">less effective</a> against new strains of the virus. The health department in one state, <a target="_blank" href="https://files.constantcontact.com/8088728e101/558b11b0-e00f-47d7-8ec1-645904ec1905.pdf">New Mexico</a>, has recommended against using it.HHS did not make officials available for an interview or answer written questions about the commercialization plans.The government created a potential workaround when they moved 
bebtelovimab, another COVID treatment, to the private market this 
summer. It now retails for $2,100 per patient. The agency set aside the 
remaining 60,000 government-purchased doses that hospitals could use to 
treat uninsured patients in a convoluted <a target="_blank" href="https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Bebtelovimab/Pages/default.aspx">dose-replacement process</a>. But it’s hard to tell how well that setup would work for Paxlovid: Bebtelovimab was already much less popular, and the FDA <a target="_blank" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region">halted its use</a> on Nov. 30 because it’s less effective against current strains of the virus.Federal officials and insurance companies would have good reason to 
make sure patients can continue to afford covid drugs: They’re far 
cheaper than if patients land in the emergency room.“The medications are so worthwhile,” said Madoff, the Massachusetts 
health official. “They’re not expensive in the grand scheme of health 
care costs.”<a target="_blank" href="https://www.khn.org/about-us">KHN</a> 
(Kaiser Health News) is a national newsroom that produces in-depth 
journalism about health issues. Together with Policy Analysis and 
Polling, KHN is one of the three major operating programs at <a target="_blank" href="https://www.kff.org/about-us">KFF</a> (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

COVID treatment Paxlovid has been free; now comes the sticker shock

TOPEKA&nbsp;– Governor Laura Kelly and the Kansas Department of Health and Environment (KDHE) on Thursday announced their continued efforts to shift to the next chapter of the COVID-19 response, pivoting from emergency pandemic response to endemic normalcy. 

On April 1, KDHE will make changes to continue the transition from emergency response to our ‘new normal,’ which includes life with COVID-19—similar to how we deal with other recurring diseases like the flu. Using the lessons learned over the past two years, KDHE will continue to ensure the State is prepared for potential surges or other needs that might arise in the future.

"Kansas is continuing the transition to a new phase of understanding and living with COVID-19,”&nbsp;Governor Laura Kelly said.&nbsp;“We know the pandemic is not over, however we now have the tools and knowledge obtained over the past two years to prevent or reduce the spread of the virus. We are normalizing our COVID-19 response and incorporating these lessons into our larger efforts at improving health outcomes for all Kansans, which includes work on multiple diseases and an awareness of differing risk factors.”

This decision comes as current COVID-19 metrics are moving in the right direction. Over the last two years, KDHE has made significant progress in keeping Kansas communities safe with the help of partners throughout the State: over 7 million tests have been given, over 4 million vaccines have been administered, and over 78% of eligible Kansans have received at least one dose of a COVID vaccine.

“In our new normal, we will continue to ensure that Kansans have equitable access to life-saving vaccines, tests, and treatments. This shift does not mean that COVID is over, but rather we are working to manage the disease in a way that allows us to maintain a more normal life that is once again filled with friends, families and other loved ones,”&nbsp;said KDHE Secretary Janet Stanek.

Working with Local Health Departments (LHDs) and stakeholders, KDHE’s endemic plan addresses six key areas that are designed to ensure the safety and wellbeing of all Kansans:

Across each of the above areas, KDHE will remain prepared to ramp up capacity to quickly respond to a surge and keep Kansans safe should the need arise.

TOPEKA&nbsp;– Governor Laura Kelly and the Kansas Department of Health and Environment (KDHE) on Thursday announced their continued efforts to shift to the next chapter of the COVID-19 response, pivoting from emergency pandemic response to endemic normalcy. On April 1, KDHE will make changes to continue the transition from emergency response to our ‘new normal,’ which includes life with COVID-19—similar to how we deal with other recurring diseases like the flu. Using the lessons learned over the past two years, KDHE will continue to ensure the State is prepared for potential surges or other needs that might arise in the future."Kansas is continuing the transition to a new phase of understanding and living with COVID-19,”&nbsp;Governor Laura Kelly said.&nbsp;“We know the pandemic is not over, however we now have the tools and knowledge obtained over the past two years to prevent or reduce the spread of the virus. We are normalizing our COVID-19 response and incorporating these lessons into our larger efforts at improving health outcomes for all Kansans, which includes work on multiple diseases and an awareness of differing risk factors.”This decision comes as current COVID-19 metrics are moving in the right direction. Over the last two years, KDHE has made significant progress in keeping Kansas communities safe with the help of partners throughout the State: over 7 million tests have been given, over 4 million vaccines have been administered, and over 78% of eligible Kansans have received at least one dose of a COVID vaccine.“In our new normal, we will continue to ensure that Kansans have equitable access to life-saving vaccines, tests, and treatments. This shift does not mean that COVID is over, but rather we are working to manage the disease in a way that allows us to maintain a more normal life that is once again filled with friends, families and other loved ones,”&nbsp;said KDHE Secretary Janet Stanek.Working with Local Health Departments (LHDs) and stakeholders, KDHE’s endemic plan addresses six key areas that are designed to ensure the safety and wellbeing of all Kansans:<ul>
 <li>Intervention:&nbsp;KDHE will continue to provide comprehensive guidance, while continuing to offer additional assistance to underserved and/or vulnerable populations.</li><li>Vaccination:&nbsp;KDHE will focus on making sure vulnerable populations have access to the COVID-19 vaccine while existing vaccine providers, including health care providers, pharmacists, hospitals, and LHDs, will continue to serve the broader population.</li><li>Treatment:&nbsp;KDHE will continue to ensure Kansans will be able to receive COVID-19 treatment across the State, as treatment distribution shifts away from public health entities and back to local health care providers.</li><li>Testing:&nbsp;KDHE will continue to support access to free testing across the state through community testing sites, LHDs, and K-12 schools as long as federal funding is available. In addition, the federal government provides direct testing support to Federally Qualified Health Centers and pharmacies around the state. To find a free testing location near you, go to&nbsp;<a href="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjAzMzEuNTU3NDY5ODEiLCJ1cmwiOiJodHRwczovL3d3dy5jb3JvbmF2aXJ1cy5rZGhla3MuZ292LzI4MC9DT1ZJRC0xOS1UZXN0aW5nIn0.GfHL9b4jMqHPXXa-raViSl3-9DLuVjAXv4mI1BPx2bo/s/1303160919/br/128948992477-l" target="_blank">knowbeforeyougoKS.com</a>. KDHE testing support for Long Term Care Facilities will be phased out&nbsp;on May 15, 2022,&nbsp;and testing support for employers&nbsp;ends on June 30, 2022.&nbsp;</li><li>Monitoring:&nbsp;KDHE will continue to monitor data as reported by organizations and facilities across the state to understand the status of COVID-19 and proactively identify at-risk groups. Public reporting will be reduced to once a week.</li><li>Communications:&nbsp;KDHE will continue to provide essential and accessible COVID information to keep Kansans safe and aware of any subsequent changes to COVID-19 response efforts.</li>
 </ul>Across each of the above areas, KDHE will remain prepared to ramp up capacity to quickly respond to a surge and keep Kansans safe should the need arise.

Gov.: Pandemic not over; Kan. moves to endemic phase of COVID response

With coronavirus cases rising in parts of Europe and Asia, scientists worry that an extra-contagious version of the omicron variant may soon push cases up in the United States too.

Experts are also keeping their eyes on another mutant: a rare delta-omicron hybrid that they say doesn’t pose much of a threat right now but shows how wily the coronavirus can be.

The U.S. will likely see an uptick in cases caused by the omicron descendant BA.2 starting in the next few weeks, according to Dr. Eric Topol, head of Scripps Research Translational Institute.

“It’s inevitable we will see a BA.2 wave here,” he said.

One reason? After about two months of falling COVID-19 cases, pandemic restrictions have been lifted across the U.S. Many people are taking off their masks and returning to indoor spaces like restaurants and theaters.

And the latest data from the Centers for Disease Control and Prevention shows&nbsp;<a href="https://covid.cdc.gov/covid-data-tracker/#variant-proportions" target="_blank">the share caused by BA.2 is up significantly.</a>&nbsp;The CDC reported Tuesday that the variant accounted for about 35% of new infections last week. In the Northeast, it was about half.

Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told ABC’s “This Week” over the weekend that he also thinks the U.S. will likely face an “uptick” similar to what’s happening in Europe, particularly the United Kingdom, where BA.2 is the dominant strain. He said he doesn’t think it will be a “surge.”

The U.K. has “had the same situation as we’ve had now,” Fauci said. “They have BA.2. They have a relaxation of some restrictions such as indoor masking and there’s a waning of immunity” from vaccines and past infections.

Keri Althoff, a researcher at Johns Hopkins Bloomberg School of Public Health, cautioned that CDC case counts underestimate the true numbers because some people are no longer getting tested and others are testing at home and not reporting the results. Also, she said, not every specimen is genetically sequenced to determine the variant.

It’s clear, she said, “BA.2 is coming onto the scene.”

One reason the variant has gained ground, scientists say,&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-science-health-world-health-organization-public-health-7e4cd2f5f6cd2ec87393b3cc9ce41c9c">is that it’s about 30% more contagious than the original omicron</a>. In rare cases, research shows it can sicken people even if they’ve already had an omicron infection — although it doesn’t seem to cause more severe disease.

Vaccines appear just as effective against both types of omicron, but breakthrough infections are possible. And experts point out that vaccination rates are lower in the U.S. than the U.K. About 74% of those 12 and older are fully vaccinated in the U.S, compared with 86% in the U.K.

”We need to emphasize that we’re not protected in this country compared to peer countries,” Topol said.

Still, not all experts are equally concerned about a BA.2-related rise in U.S. cases. Dr. James Musser, head of genomic medicine and infectious diseases at Houston Methodist, said the variant has so far only caused about 1% to 3% of cases in his medical system. Cases there have usually tracked closely with what’s happening in the U.K.

He called BA.2 “something we’re keeping an eye on,” but said, “I’m not losing sleep” over it.

That’s how many scientists view the other variant that some in the public are calling “deltacron,” a hybrid containing genetic information from both delta and omicron.

Earlier this month, Maria Van Kerkhove of the World Health Organization said the hybrid has been detected at “very low levels” in France, the Netherlands and Denmark. And two recent studies, which have not yet been peer-reviewed, point to a tiny number of cases in the U.S.

Much remains unknown about the hybrid. There’s no evidence it causes more severe disease, and it doesn’t look like it’s infecting many people. CDC researchers identified 9 samples, seven from the mid-Atlantic region in a&nbsp;<a href="https://www.biorxiv.org/content/10.1101/2022.03.19.484981v1.full.pdf+html" target="_blank">study released Monday</a>&nbsp;that hasn’t yet been peer-reviewed. Topol, who was not involved in the research, said there’s no evidence it has the potential to spread.

It’s common for coronaviruses to shuffle gene segments, said Dr. Stuart Campbell Ray, an infectious disease expert at Johns Hopkins University. With two variants circulating at the same time, people may get double infections, and a “progeny virus” could emerge.

Given the virus’&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-science-health-pandemics-dc99bc9f769dd6d7cb669e3d185c6261">ability to spawn new mutants</a>&nbsp;— and the rise of BA.2 — experts say people should get vaccinated if they’re not and keep their masks handy.

“Keep your guard up,” Topol said. “This is not over.”

By LAURA UNGAR, Associated PressWith coronavirus cases rising in parts of Europe and Asia, scientists worry that an extra-contagious version of the omicron variant may soon push cases up in the United States too.Experts are also keeping their eyes on another mutant: a rare delta-omicron hybrid that they say doesn’t pose much of a threat right now but shows how wily the coronavirus can be.The U.S. will likely see an uptick in cases caused by the omicron descendant BA.2 starting in the next few weeks, according to Dr. Eric Topol, head of Scripps Research Translational Institute.“It’s inevitable we will see a BA.2 wave here,” he said.One reason? After about two months of falling COVID-19 cases, pandemic restrictions have been lifted across the U.S. Many people are taking off their masks and returning to indoor spaces like restaurants and theaters.And the latest data from the Centers for Disease Control and Prevention shows&nbsp;<a href="https://covid.cdc.gov/covid-data-tracker/#variant-proportions" target="_blank">the share caused by BA.2 is up significantly.</a>&nbsp;The CDC reported Tuesday that the variant accounted for about 35% of new infections last week. In the Northeast, it was about half.Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told ABC’s “This Week” over the weekend that he also thinks the U.S. will likely face an “uptick” similar to what’s happening in Europe, particularly the United Kingdom, where BA.2 is the dominant strain. He said he doesn’t think it will be a “surge.”The U.K. has “had the same situation as we’ve had now,” Fauci said. “They have BA.2. They have a relaxation of some restrictions such as indoor masking and there’s a waning of immunity” from vaccines and past infections.Keri Althoff, a researcher at Johns Hopkins Bloomberg School of Public Health, cautioned that CDC case counts underestimate the true numbers because some people are no longer getting tested and others are testing at home and not reporting the results. Also, she said, not every specimen is genetically sequenced to determine the variant.It’s clear, she said, “BA.2 is coming onto the scene.”One reason the variant has gained ground, scientists say,&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-science-health-world-health-organization-public-health-7e4cd2f5f6cd2ec87393b3cc9ce41c9c">is that it’s about 30% more contagious than the original omicron</a>. In rare cases, research shows it can sicken people even if they’ve already had an omicron infection — although it doesn’t seem to cause more severe disease.Vaccines appear just as effective against both types of omicron, but breakthrough infections are possible. And experts point out that vaccination rates are lower in the U.S. than the U.K. About 74% of those 12 and older are fully vaccinated in the U.S, compared with 86% in the U.K.”We need to emphasize that we’re not protected in this country compared to peer countries,” Topol said.Still, not all experts are equally concerned about a BA.2-related rise in U.S. cases. Dr. James Musser, head of genomic medicine and infectious diseases at Houston Methodist, said the variant has so far only caused about 1% to 3% of cases in his medical system. Cases there have usually tracked closely with what’s happening in the U.K.He called BA.2 “something we’re keeping an eye on,” but said, “I’m not losing sleep” over it.That’s how many scientists view the other variant that some in the public are calling “deltacron,” a hybrid containing genetic information from both delta and omicron.Earlier this month, Maria Van Kerkhove of the World Health Organization said the hybrid has been detected at “very low levels” in France, the Netherlands and Denmark. And two recent studies, which have not yet been peer-reviewed, point to a tiny number of cases in the U.S.Much remains unknown about the hybrid. There’s no evidence it causes more severe disease, and it doesn’t look like it’s infecting many people. CDC researchers identified 9 samples, seven from the mid-Atlantic region in a&nbsp;<a href="https://www.biorxiv.org/content/10.1101/2022.03.19.484981v1.full.pdf+html" target="_blank">study released Monday</a>&nbsp;that hasn’t yet been peer-reviewed. Topol, who was not involved in the research, said there’s no evidence it has the potential to spread.It’s common for coronaviruses to shuffle gene segments, said Dr. Stuart Campbell Ray, an infectious disease expert at Johns Hopkins University. With two variants circulating at the same time, people may get double infections, and a “progeny virus” could emerge.Given the virus’&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-science-health-pandemics-dc99bc9f769dd6d7cb669e3d185c6261">ability to spawn new mutants</a>&nbsp;— and the rise of BA.2 — experts say people should get vaccinated if they’re not and keep their masks handy.“Keep your guard up,” Topol said. “This is not over.”___

Scientists worry virus variant may push up COVID cases in US

TOPEKA — The number of confirmed coronavirus cases* (see below) in Kansas increased by 513 to a total of 767,482, the state health department reported Friday afternoon.&nbsp; &nbsp;

The state reported 8 additional COVID-19 deaths for a total of 7983.

<a href="https://www.kansasvaccine.gov/158/Data">Click here for Data</a> about the COVID-19 vaccine.

<a href="https://www.coronavirus.kdheks.gov/160/COVID-19-in-Kansas">Click here&nbsp;</a>for additional virus numbers from the KDHE.

As of August 1, 2021, in accordance with an&nbsp;<a href="https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/" target="_blank">updated CDC/CSTE surveillance case definition</a>, a confirmed case is defined as a person who tested positive by molecular detection (e.g., PCR, NAA) or identification of SARS-CoV-2 through genetic sequencing. A probable case is defined as a person with: a) presumptive lab evidence (antigen) or b) no lab testing but meeting clinical case criteria and is epi-linked. A person will be counted as a new surveillance case (e.g. reinfection) if they test positive for SARS-CoV-2 by a diagnostic test (i.e., molecular, antigen) and it has been greater than 90 days since the previous positive diagnostic test. In addition, a person with sequencing results identifying different SARS-CoV-2 lineages regardless of the time since the previous specimen sequenced will be counted as a new surveillance case.&nbsp;

Cases occurring between&nbsp;September 1, 2020&nbsp;and July 29, 2021 were classified by&nbsp;<a href="https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/" target="_blank">previous CDC/CSTE case definition,&nbsp;</a>and cases prior to September 1, 2020 were classified by the&nbsp;<a href="https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020/" target="_blank">original case definition</a>.

TOPEKA — The number of confirmed coronavirus cases* (see below) in Kansas increased by 513 to a total of 767,482, the state health department reported Friday afternoon.&nbsp; &nbsp;The state reported 8 additional COVID-19 deaths for a total of 7983.<a href="https://www.kansasvaccine.gov/158/Data">Click here for Data</a> about the COVID-19 vaccine.<a href="https://www.coronavirus.kdheks.gov/160/COVID-19-in-Kansas">Click here&nbsp;</a>for additional virus numbers from the KDHE.As of August 1, 2021, in accordance with an&nbsp;<a href="https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/" target="_blank">updated CDC/CSTE surveillance case definition</a>, a confirmed case is defined as a person who tested positive by molecular detection (e.g., PCR, NAA) or identification of SARS-CoV-2 through genetic sequencing. A probable case is defined as a person with: a) presumptive lab evidence (antigen) or b) no lab testing but meeting clinical case criteria and is epi-linked. A person will be counted as a new surveillance case (e.g. reinfection) if they test positive for SARS-CoV-2 by a diagnostic test (i.e., molecular, antigen) and it has been greater than 90 days since the previous positive diagnostic test. In addition, a person with sequencing results identifying different SARS-CoV-2 lineages regardless of the time since the previous specimen sequenced will be counted as a new surveillance case.&nbsp;Cases occurring between&nbsp;September 1, 2020&nbsp;and July 29, 2021 were classified by&nbsp;<a href="https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/" target="_blank">previous CDC/CSTE case definition,&nbsp;</a>and cases prior to September 1, 2020 were classified by the&nbsp;<a href="https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020/" target="_blank">original case definition</a>.

KDHE: Latest COVID-19 numbers in Kansas

Fort Riley officials have announced via social media that Irwin Army Community Hospital is closing its COVID-19 drive-thru testing site effective Feb. 25. The last available date for drive-thru testing is Thursday, Feb. 24. 

COVID-19 testing will remain available at IACH through medical appointment by calling (785) 239-3627. 

Free COVID-19 self-test kits are available at Fort Riley Public Health Department, 7665 Normandy Dr., Fort Riley, Kansas, 66442, during business hours Monday and Wednesday-Friday, 7:30 a.m. – 4 p.m., Tuesday, 9 a.m. – 4 p.m. 

Testing is available also at locations throughout the local community including pharmacies and county health departments. The Kansas Department of Health and Environment lists the following locations as community testing sites for COVID-19: 

• Kollhoff Pharmacy, 407 S Washington St, Junction City, KS 66441

• Geary County Health Department, 212 W Ash St, Junction City, KS 66441

• Riley County Health Department, 2030 Tecumseh Rd, Manhattan, KS 66502

• Hy-Vee Pharmacy, 325 Bluemont Ave, Manhattan, KS 66502

• Walgreens Pharmacy, 325 Bluemont Ave, Manhattan, KS 66502

Fort Riley officials have announced via social media that Irwin Army Community Hospital is closing its COVID-19 drive-thru testing site effective Feb. 25. The last available date for drive-thru testing is Thursday, Feb. 24. COVID-19 testing will remain available at IACH through medical appointment by calling (785) 239-3627. Free COVID-19 self-test kits are available at Fort Riley Public Health Department, 7665 Normandy Dr., Fort Riley, Kansas, 66442, during business hours Monday and Wednesday-Friday, 7:30 a.m. – 4 p.m., Tuesday, 9 a.m. – 4 p.m. Testing is available also at locations throughout the local community including pharmacies and county health departments. The Kansas Department of Health and Environment lists the following locations as community testing sites for COVID-19: • Kollhoff Pharmacy, 407 S Washington St, Junction City, KS 66441• Geary County Health Department, 212 W Ash St, Junction City, KS 66441• Riley County Health Department, 2030 Tecumseh Rd, Manhattan, KS 66502• Hy-Vee Pharmacy, 325 Bluemont Ave, Manhattan, KS 66502• Walgreens Pharmacy, 325 Bluemont Ave, Manhattan, KS 66502

Drive-through testing site on Post will close this week

Geary County Interim Health Department Director Charles Martinez said this week that the county ranks third among Kansas counties for COVID-19 vaccinations. Martinez informed the county commission he thought Geary County had reached the peak of the Omicron variant and numbers are already down. "There's light at the end of the tunnel."

There have been staff shortages but people are returning to work.&nbsp;

Geary County Interim Health Department Director Charles Martinez said this week that the county ranks third among Kansas counties for COVID-19 vaccinations. Martinez informed the county commission he thought Geary County had reached the peak of the Omicron variant and numbers are already down. "There's light at the end of the tunnel."There have been staff shortages but people are returning to work.&nbsp;

Geary County ranks third in COVID-19 vaccination rate

WASHINGTON (AP) —The fast-moving omicron variant may cause less severe disease on average, but COVID-19 deaths in the U.S. are climbing and modelers forecast 50,000 to 300,000 more Americans could die by the time the wave subsides in mid-March.

The seven-day rolling average for daily new COVID-19 deaths in the U.S. has been trending upward since mid-November, reaching nearly 1,700 on Jan. 17 — still below the peak of 3,300 in January 2021. COVID-19 deaths among nursing home residents&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-health-pandemics-nursing-homes-centers-for-disease-control-and-prevention-31685a926b0ee4e97e1b314a52b1f41c">started rising slightly two weeks ago</a>, although still at a rate 10 times less than last year before most residents were vaccinated.

Despite signs omicron causes milder disease on average, the unprecedented level of infection spreading through the country, with cases still soaring in many states, means many vulnerable people will become severely sick. If the higher end of projections comes to pass, that would push total U.S. deaths from COVID-19 over 1 million by early spring.

“A lot of people are still going to die because of how transmissible omicron has been,” said University of South Florida epidemiologist Jason Salemi. “It unfortunately is going to get worse before it gets better.”

Morgues are starting to run out of space in Johnson County, Kansas, said Dr. Sanmi Areola, director of the health department. More than 30 residents have died in the county this year, the vast majority of them unvaccinated.

But the notion that a generally less severe variant could still take the lives of thousands of people has been difficult for health experts to convey. The math of it — that a small percentage of a very high number of infections can yield a very high number of deaths — is difficult to visualize.

“Overall, you’re going to see more sick people even if you as an individual have a lower chance of being sick,” said Katriona Shea of Pennsylvania State University, who co-leads a team that pulls together&nbsp;<a href="https://covid19scenariomodelinghub.org/" target="_blank">several pandemic models</a>&nbsp;and shares the combined projections with the White House.

The wave of deaths heading for the United States will crest in late January or early February, Shea said. In early February, weekly deaths could equal or exceed the delta peak, and possibly even surpass the previous U.S. peak in deaths last year.

Some unknown portion of these deaths are among people infected with the delta variant, but experts say omicron is also claiming lives.

“This is omicron driven,” Shea said of the coming wave of deaths. The combined models project 1.5 million Americans will be hospitalized and 191,000 will die from mid-December through mid-March. Taking into account the uncertainty in the models, U.S. deaths during the omicron wave could range from 58,000 to 305,000.

Yet, it’s become increasingly clear that the risk from omicron is lower than from previous variants. New evidence from nearly 70,000 patients in Southern California suggests omicron is causing milder illness than delta.

A study, posted online and cited during a recent White House briefing, found patients with omicron had a 53% lower risk of hospitalization with respiratory symptoms, a 74% lower risk of ICU admission, and a 91% lower risk of death. The study, which has not yet been peer reviewed, comes from researchers at Kaiser Permanente and University of California, Berkeley.

“It’s hard for me to say straight out it’s good news,” said study co-author Sara Y. Tartof, a Kaiser Permanente research scientist. “Maybe there’s good news in the sense that if you are infected your chance of becoming severely ill are decreased, but from a societal perspective it’s a very heavy burden for us. It remains a serious situation, and we need to maintain practices and behaviors we know protect us.”

Overburdened hospitals could also contribute to more deaths, said Marc Lipsitch of Harvard T.H. Chan School of Public Health and scientific director of the Centers for Disease Control and Prevention’s forecasting center.

“In places with extremely short staffing and overloads of patients, as the medical professionals have been telling us, the quality of care begins to suffer,” Lipsitch said. “That may also lead to higher death rates, but that’s not in any of the models that I’m aware of.”

WASHINGTON (AP) —The fast-moving omicron variant may cause less severe disease on average, but COVID-19 deaths in the U.S. are climbing and modelers forecast 50,000 to 300,000 more Americans could die by the time the wave subsides in mid-March.The seven-day rolling average for daily new COVID-19 deaths in the U.S. has been trending upward since mid-November, reaching nearly 1,700 on Jan. 17 — still below the peak of 3,300 in January 2021. COVID-19 deaths among nursing home residents&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-health-pandemics-nursing-homes-centers-for-disease-control-and-prevention-31685a926b0ee4e97e1b314a52b1f41c">started rising slightly two weeks ago</a>, although still at a rate 10 times less than last year before most residents were vaccinated.Despite signs omicron causes milder disease on average, the unprecedented level of infection spreading through the country, with cases still soaring in many states, means many vulnerable people will become severely sick. If the higher end of projections comes to pass, that would push total U.S. deaths from COVID-19 over 1 million by early spring.“A lot of people are still going to die because of how transmissible omicron has been,” said University of South Florida epidemiologist Jason Salemi. “It unfortunately is going to get worse before it gets better.”Morgues are starting to run out of space in Johnson County, Kansas, said Dr. Sanmi Areola, director of the health department. More than 30 residents have died in the county this year, the vast majority of them unvaccinated.But the notion that a generally less severe variant could still take the lives of thousands of people has been difficult for health experts to convey. The math of it — that a small percentage of a very high number of infections can yield a very high number of deaths — is difficult to visualize.“Overall, you’re going to see more sick people even if you as an individual have a lower chance of being sick,” said Katriona Shea of Pennsylvania State University, who co-leads a team that pulls together&nbsp;<a href="https://covid19scenariomodelinghub.org/" target="_blank">several pandemic models</a>&nbsp;and shares the combined projections with the White House.The wave of deaths heading for the United States will crest in late January or early February, Shea said. In early February, weekly deaths could equal or exceed the delta peak, and possibly even surpass the previous U.S. peak in deaths last year.Some unknown portion of these deaths are among people infected with the delta variant, but experts say omicron is also claiming lives.“This is omicron driven,” Shea said of the coming wave of deaths. The combined models project 1.5 million Americans will be hospitalized and 191,000 will die from mid-December through mid-March. Taking into account the uncertainty in the models, U.S. deaths during the omicron wave could range from 58,000 to 305,000.Yet, it’s become increasingly clear that the risk from omicron is lower than from previous variants. New evidence from nearly 70,000 patients in Southern California suggests omicron is causing milder illness than delta.A study, posted online and cited during a recent White House briefing, found patients with omicron had a 53% lower risk of hospitalization with respiratory symptoms, a 74% lower risk of ICU admission, and a 91% lower risk of death. The study, which has not yet been peer reviewed, comes from researchers at Kaiser Permanente and University of California, Berkeley.“It’s hard for me to say straight out it’s good news,” said study co-author Sara Y. Tartof, a Kaiser Permanente research scientist. “Maybe there’s good news in the sense that if you are infected your chance of becoming severely ill are decreased, but from a societal perspective it’s a very heavy burden for us. It remains a serious situation, and we need to maintain practices and behaviors we know protect us.”Overburdened hospitals could also contribute to more deaths, said Marc Lipsitch of Harvard T.H. Chan School of Public Health and scientific director of the Centers for Disease Control and Prevention’s forecasting center.“In places with extremely short staffing and overloads of patients, as the medical professionals have been telling us, the quality of care begins to suffer,” Lipsitch said. “That may also lead to higher death rates, but that’s not in any of the models that I’m aware of.”___

Report: US faces wave of omicron deaths in coming weeks

WASHINGTON (AP) — President Joe Biden announced Thursday that the government will double to 1 billion the rapid, at-home COVID-19 tests to be distributed free to Americans, along with the most protective N95 masks, as he highlighted his efforts to “surge” resources to help the country weather the spike in coronavirus cases.

Biden also announced that starting next week 1,000 military medical personnel will begin deploying across the country to help overwhelmed medical facilities ease&nbsp;<a href="https://apnews.com/article/business-health-coronavirus-pandemic-b6d58e41b209dd67ed0954f28b542baf">staff shortages</a>&nbsp;due to&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-health-europe-london-england-eddf1657a9462547826881562b71f3b7">the highly transmissible omicron variant</a>.

Many facilities are struggling because their workers are in at-home quarantines due to the virus at the same time as a nationwide spike in COVID-19 cases. The new deployments will be on top of other federal medical personnel who have already been sent to states to help with acute shortages.

Speaking at the White House Thursday, Biden acknowledged that, “I know we’re all frustrated as we enter this new year” as virus cases reach new heights. But he insisted that it remains “a pandemic of the unvaccinated.”

Both vaccinated and unvaccinated people test positive for the virus, but Biden noted medical figures showing that people are far less likely to suffer serious illness and death if they’ve received a shot: “What happens after that could not be more different.”

Biden’s comments come as his administration’s focus is shifting to easing disruptions from the spike in cases that is also contributing to&nbsp;<a href="https://apnews.com/article/grocery-store-supply-chain-issues-166cc40b0ff095af9d0bf4041fa1b5fc">grocery shortages</a>&nbsp;and&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-travel-flight-cancellations-bed3b491ef8dfd778ac612e35add75fb">flight cancellations,&nbsp;</a>rather than preventing the transmission of the virus.

On Tuesday, Janet Woodcock, the acting head of the Food and Drug Administration, told Congress that the highly transmissible strain will infect “most people” and that the focus should turn to ensuring critical services can continue uninterrupted.

“I think it’s hard to process what’s actually happening right now, which is: Most people are going to get COVID, all right?” she said. “What we need to do is make sure the hospitals can still function — transportation, other essential services are not disrupted while this happens.”

Biden said that he is directing his team to double its procurement of rapid COVID-19 tests to be delivered for free to Americans through a forthcoming federal website, as he seeks to respond to criticism over&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-joe-biden-science-travel-health-196255dcfe3e928b6f9f5779cd47be4e">shortages and long lines for tests</a>. The initial order was for 500 million tests, and now the federal government will purchase 1 billion at-home testing kits. Biden said the website will launch next week.

Biden also announced that for the first time his administration was planning to make high-quality N95 masks, which are most effective at preventing transmission of the virus, available for free. He said his administration would announce details next week.

The federal government has a stockpile of more than 750 million N95 masks, the White House said this week. And though research has shown those masks to be better protection, they are often more uncomfortable, and health officials are not altering their guidance to recommend against less-protective cloth masks.

The best mask “is the one that you will wear and the one you can keep on all day long, that you can tolerate in public indoor settings,” Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said Wednesday.

Biden encouraged Americans to wear masks when indoors to slow the spread of the virus, even as he acknowledged they’re a “pain in the neck”

During Thursday’s remarks Biden was joined by&nbsp;<a href="https://apnews.com/article/joe-biden-biden-cabinet-lloyd-austin-john-cornyn-army-4d8848273e4e1fe6e4ad2dc8cee7313c">Defense Secretary Lloyd Austin</a>, who recently recovered from&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-joe-biden-health-lloyd-austin-alejandro-mayorkas-d06d9606206265e8fae110cf7a549fd4">his own case of COVID-19</a>, and&nbsp;<a href="https://apnews.com/article/joe-biden-politics-new-york-coronavirus-pandemic-emergency-management-49cff31bd6d423da5379523f99835eef">FEMA Administrator Deanne Criswell</a>. They were hearing about the work of the more than 800 military personnel who have been helping civilian hospitals since Thanksgiving and the more than 14,000&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-business-health-new-hampshire-dover-7352b829ecb9ca54d89df03fa6fd9191">National Guard members</a>&nbsp;whose work supporting vaccinations, testing and caring for patients is being covered by the federal government.

The White House said the they spoke with federal personnel who are already on the ground in Arizona, Michigan and New York to hear about their experiences.

Biden also announced that six additional military medical teams will be deployed to Michigan, New Jersey, New Mexico, New York, Ohio and Rhode Island.

The White House said the teams will support Henry Ford Hospital just outside Detroit, University Hospital in Newark, the University of New Mexico hospital in Albuquerque, Coney Island Hospital in Brooklyn, Cleveland Clinic and Rhode Island Hospital in Providence.

WASHINGTON (AP) — President Joe Biden announced Thursday that the government will double to 1 billion the rapid, at-home COVID-19 tests to be distributed free to Americans, along with the most protective N95 masks, as he highlighted his efforts to “surge” resources to help the country weather the spike in coronavirus cases.<div><iframe src="https://www.facebook.com/plugins/video.php?height=314&href=https%3A%2F%2Fwww.facebook.com%2FWhiteHouse%2Fvideos%2F627100008618297%2F&show_text=false&width=560&t=17" width="560" height="314" style="border:none;overflow:hidden" scrolling="no" frameborder="0" allowfullscreen="true" allow="autoplay; clipboard-write; encrypted-media; picture-in-picture; web-share" allowFullScreen="true"></iframe></div>Biden also announced that starting next week 1,000 military medical personnel will begin deploying across the country to help overwhelmed medical facilities ease&nbsp;<a href="https://apnews.com/article/business-health-coronavirus-pandemic-b6d58e41b209dd67ed0954f28b542baf">staff shortages</a>&nbsp;due to&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-health-europe-london-england-eddf1657a9462547826881562b71f3b7">the highly transmissible omicron variant</a>.<div><blockquote class="twitter-tweet">President Biden just announced that our administration will purchase an additional 500 million COVID-19 at home tests, bringing the total number of tests that will be distributed for free to 1 billion. <a href="https://t.co/Ze8NSyKaf9">pic.twitter.com/Ze8NSyKaf9</a>&mdash; The White House (@WhiteHouse) <a href="https://twitter.com/WhiteHouse/status/1481654833199259649?ref_src=twsrc%5Etfw">January 13, 2022</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>Many facilities are struggling because their workers are in at-home quarantines due to the virus at the same time as a nationwide spike in COVID-19 cases. The new deployments will be on top of other federal medical personnel who have already been sent to states to help with acute shortages.Speaking at the White House Thursday, Biden acknowledged that, “I know we’re all frustrated as we enter this new year” as virus cases reach new heights. But he insisted that it remains “a pandemic of the unvaccinated.”Both vaccinated and unvaccinated people test positive for the virus, but Biden noted medical figures showing that people are far less likely to suffer serious illness and death if they’ve received a shot: “What happens after that could not be more different.”Biden’s comments come as his administration’s focus is shifting to easing disruptions from the spike in cases that is also contributing to&nbsp;<a href="https://apnews.com/article/grocery-store-supply-chain-issues-166cc40b0ff095af9d0bf4041fa1b5fc">grocery shortages</a>&nbsp;and&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-travel-flight-cancellations-bed3b491ef8dfd778ac612e35add75fb">flight cancellations,&nbsp;</a>rather than preventing the transmission of the virus.On Tuesday, Janet Woodcock, the acting head of the Food and Drug Administration, told Congress that the highly transmissible strain will infect “most people” and that the focus should turn to ensuring critical services can continue uninterrupted.“I think it’s hard to process what’s actually happening right now, which is: Most people are going to get COVID, all right?” she said. “What we need to do is make sure the hospitals can still function — transportation, other essential services are not disrupted while this happens.”Biden said that he is directing his team to double its procurement of rapid COVID-19 tests to be delivered for free to Americans through a forthcoming federal website, as he seeks to respond to criticism over&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-joe-biden-science-travel-health-196255dcfe3e928b6f9f5779cd47be4e">shortages and long lines for tests</a>. The initial order was for 500 million tests, and now the federal government will purchase 1 billion at-home testing kits. Biden said the website will launch next week.Biden also announced that for the first time his administration was planning to make high-quality N95 masks, which are most effective at preventing transmission of the virus, available for free. He said his administration would announce details next week.The federal government has a stockpile of more than 750 million N95 masks, the White House said this week. And though research has shown those masks to be better protection, they are often more uncomfortable, and health officials are not altering their guidance to recommend against less-protective cloth masks.The best mask “is the one that you will wear and the one you can keep on all day long, that you can tolerate in public indoor settings,” Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said Wednesday.Biden encouraged Americans to wear masks when indoors to slow the spread of the virus, even as he acknowledged they’re a “pain in the neck”During Thursday’s remarks Biden was joined by&nbsp;<a href="https://apnews.com/article/joe-biden-biden-cabinet-lloyd-austin-john-cornyn-army-4d8848273e4e1fe6e4ad2dc8cee7313c">Defense Secretary Lloyd Austin</a>, who recently recovered from&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-joe-biden-health-lloyd-austin-alejandro-mayorkas-d06d9606206265e8fae110cf7a549fd4">his own case of COVID-19</a>, and&nbsp;<a href="https://apnews.com/article/joe-biden-politics-new-york-coronavirus-pandemic-emergency-management-49cff31bd6d423da5379523f99835eef">FEMA Administrator Deanne Criswell</a>. They were hearing about the work of the more than 800 military personnel who have been helping civilian hospitals since Thanksgiving and the more than 14,000&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-business-health-new-hampshire-dover-7352b829ecb9ca54d89df03fa6fd9191">National Guard members</a>&nbsp;whose work supporting vaccinations, testing and caring for patients is being covered by the federal government.The White House said the they spoke with federal personnel who are already on the ground in Arizona, Michigan and New York to hear about their experiences.Biden also announced that six additional military medical teams will be deployed to Michigan, New Jersey, New Mexico, New York, Ohio and Rhode Island.The White House said the teams will support Henry Ford Hospital just outside Detroit, University Hospital in Newark, the University of New Mexico hospital in Albuquerque, Coney Island Hospital in Brooklyn, Cleveland Clinic and Rhode Island Hospital in Providence.

🎥 Biden now offering 1 billion free COVID tests to fight omicron

TOPEKA— The number of confirmed coronavirus cases in Kansas was much larger to end 2021 than on New Year's Day a year ago.

On January 1, 2021, the Kansas Department of Health reported an increase of 5,312 cases of COVID to a total of 227,745 statewide. Coronavirus deaths were reported at 2,879 an increase of 138.

<a href="https://www.kansasvaccine.gov/158/Data">Click here for Data</a>&nbsp;about the COVID-19 vaccine.

This year, due to the holiday, the KDHE released no new numbers on New Year's Eve Friday. On Wednesday, the state reported an increase of 7,083 COVID cases for a total of 519,544. The state reported 37 additional COVID-19 deaths on Wednesday for a total of 7,001 since the beginning of the pandemic.

As of August 1, 2021, in accordance with an&nbsp;<a href="https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/" target="_blank">updated CDC/CSTE surveillance case definition</a>, a confirmed case is defined as a person who tested positive by molecular detection&nbsp;(e.g., PCR, NAA) or identification of SARS-CoV-2 through genetic sequencing. A probable case is defined as a person with: a) presumptive lab evidence (antigen) or b) no lab testing but meeting clinical case criteria and is epi-linked. A person will be counted as a new surveillance case (e.g. reinfection) if they test positive for SARS-CoV-2 by a diagnostic test (i.e., molecular, antigen) and it has been greater than 90 days since the previous positive diagnostic test. In addition, a person with sequencing results identifying different SARS-CoV-2 lineages regardless of the time since the previous specimen sequenced will be counted as a new surveillance case.&nbsp;

TOPEKA— The number of confirmed coronavirus cases in Kansas was much larger to end 2021 than on New Year's Day a year ago.On January 1, 2021, the Kansas Department of Health reported an increase of 5,312 cases of COVID to a total of 227,745 statewide. Coronavirus deaths were reported at 2,879 an increase of 138.<figure>
 <img src="https://media.eaglewebservices.com/public/2021/1/1609526207240.png" alt="Friday Jan. 1, 2021 KDHE image" />
 <figcaption>Friday Jan. 1, 2021 KDHE image</figcaption>
 </figure><a href="https://www.kansasvaccine.gov/158/Data">Click here for Data</a>&nbsp;about the COVID-19 vaccine.<a href="https://www.coronavirus.kdheks.gov/160/COVID-19-in-Kansas">Click here&nbsp;</a>for additional virus numbers from the KDHE.This year, due to the holiday, the KDHE released no new numbers on New Year's Eve Friday. On Wednesday, the state reported an increase of 7,083 COVID cases for a total of 519,544. The state reported 37 additional COVID-19 deaths on Wednesday for a total of 7,001 since the beginning of the pandemic.<figure>
 <img src="https://media.eaglewebservices.com/public/2021/12/1640805043111.png" alt="Wednesday Dec. 29, 2021 KDHE image" />
 <figcaption>Wednesday Dec. 29, 2021 KDHE image</figcaption>
 </figure>As of August 1, 2021, in accordance with an&nbsp;<a href="https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/" target="_blank">updated CDC/CSTE surveillance case definition</a>, a confirmed case is defined as a person who tested positive by molecular detection&nbsp;(e.g., PCR, NAA) or identification of SARS-CoV-2 through genetic sequencing. A probable case is defined as a person with: a) presumptive lab evidence (antigen) or b) no lab testing but meeting clinical case criteria and is epi-linked. A person will be counted as a new surveillance case (e.g. reinfection) if they test positive for SARS-CoV-2 by a diagnostic test (i.e., molecular, antigen) and it has been greater than 90 days since the previous positive diagnostic test. In addition, a person with sequencing results identifying different SARS-CoV-2 lineages regardless of the time since the previous specimen sequenced will be counted as a new surveillance case.&nbsp;Cases occurring between&nbsp;September 1, 2020&nbsp;and July 29, 2021 were classified by&nbsp;<a href="https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/" target="_blank">previous CDC/CSTE case definition,&nbsp;</a>and cases prior to September 1, 2020 were classified by the&nbsp;<a href="https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020/" target="_blank">original case definition</a>.

KDHE: Comparing COVID numbers from New Year's Day 2021

TOPEKA— Governor Laura Kelly says Kansas will encourage its public schools to hold clinics for vaccinating children ages 5 through 11 against COVID-19. 

She said Wednesday during the Safer Classrooms Workgroup virtual meeting that some doses already have arrived in the state. Kansas expects to receive nearly 128,000 doses of a vaccine for younger children manufactured by Pfizer by next week.

The governor announced that all children in the 5-11 age group immediately will be eligible for shots and that most of the doses should be in the state by Friday. The doses would be enough for 46% of the state's children ages 5 through 11 to get the first of two shots.

The state is following recommendations from the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention on vaccinating children.

Federal health authorities gave the final go-ahead Tuesday for a vaccine made by Pfizer for younger children.

TOPEKA— Governor Laura Kelly says Kansas will encourage its public schools to hold clinics for vaccinating children ages 5 through 11 against COVID-19. <div><iframe width="560" height="315" src="https://www.youtube.com/embed/Cdn1YlkaONE?start=144" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe></div>She said Wednesday during the Safer Classrooms Workgroup virtual meeting that some doses already have arrived in the state. Kansas expects to receive nearly 128,000 doses of a vaccine for younger children manufactured by Pfizer by next week.The governor announced that all children in the 5-11 age group immediately will be eligible for shots and that most of the doses should be in the state by Friday. The doses would be enough for 46% of the state's children ages 5 through 11 to get the first of two shots.The state is following recommendations from the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention on vaccinating children.Federal health authorities gave the final go-ahead Tuesday for a vaccine made by Pfizer for younger children.

🎥 Gov. Kelly encourages schools to hold COVID vaccine clinics 

TOPEKA —Governor Kelly discussed Kansas' plan to vaccinate children ages 5-11 years-old at the Safer Classrooms Workgroup virtual meeting Wednesday. It began just after 1p.m.

The state expects to receive nearly 128,000 doses of a COVID-19 vaccine for children aged 5 through 11 next week, and the state also announced Wednesday that all of them will be eligible for shots. 

According to Gov. Kelly, Kansas is following recommendations from the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention on vaccinating children. 

Kansas has about 276,000 children from 5 through 11, and the doses it expects to receive will be enough for 46% of them to get the first of two shots. Federal health authorities gave the final go-ahead Tuesday for a vaccine made by Pfizer for younger children.

TOPEKA —Governor Kelly discussed Kansas' plan to vaccinate children ages 5-11 years-old at the Safer Classrooms Workgroup virtual meeting Wednesday. It began just after 1p.m.<div><iframe width="560" height="315" src="https://www.youtube.com/embed/Cdn1YlkaONE?start=144" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe></div>The state expects to receive nearly 128,000 doses of a COVID-19 vaccine for children aged 5 through 11 next week, and the state also announced Wednesday that all of them will be eligible for shots. According to Gov. Kelly, Kansas is following recommendations from the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention on vaccinating children. Kansas has about 276,000 children from 5 through 11, and the doses it expects to receive will be enough for 46% of them to get the first of two shots. Federal health authorities gave the final go-ahead Tuesday for a vaccine made by Pfizer for younger children.

🎥 Governor on Kansas plan to vaccinate kids age 5-11 

ATLANTA (AP) —U.S. health officials on Tuesday gave the final signoff to Pfizer’s kid-size COVID-19 shot, a major expansion of the nation’s vaccination campaign.

The Food and Drug Administration already authorized the shots for children ages 5 to 11 — doses just a third of the amount given to teens and adults. But the Centers for Disease Control and Prevention recommends who should receive FDA-cleared vaccines.

The announcement by CDC director Dr. Rochelle Walensky came only hours after an advisory panel unanimously decided Pfizer’s shots should be opened to the 28 million youngsters in that age group.

Millions of shots made by Pfizer and its partner BioNTech have already been shipped to states, doctors’ offices and pharmacies, to be ready for CDC’s decision.

<figure>
 <img src="https://media.eaglewebservices.com/public/2021/11/1635890433225.png" alt="CDC Director Rochelle Walensky" />
 <figcaption>CDC Director Rochelle Walensky</figcaption>
 </figure>ATLANTA (AP) —U.S. health officials on Tuesday gave the final signoff to Pfizer’s kid-size COVID-19 shot, a major expansion of the nation’s vaccination campaign.The Food and Drug Administration already authorized the shots for children ages 5 to 11 — doses just a third of the amount given to teens and adults. But the Centers for Disease Control and Prevention recommends who should receive FDA-cleared vaccines.<figure>
 <img src="https://media.eaglewebservices.com/public/2021/10/1635537216378.png" alt="The vaccine for children has an orange cap-Photo courtesy Pfizer" />
 <figcaption>The vaccine for children has an orange cap-Photo courtesy Pfizer</figcaption>
 </figure>The announcement by CDC director Dr. Rochelle Walensky came only hours after an advisory panel unanimously decided Pfizer’s shots should be opened to the 28 million youngsters in that age group.Millions of shots made by Pfizer and its partner BioNTech have already been shipped to states, doctors’ offices and pharmacies, to be ready for CDC’s decision.___

US gives final clearance to COVID-19 shots for kids 5 to 11

The&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-five-million-dead-memorials-acd5a25aabb50f203c8ee059803a1bec">global death toll</a>&nbsp;from COVID-19 topped 5 million on Monday, less than two years into a crisis that has not only devastated poor countries but also humbled wealthy ones with first-rate health care systems.

Together, the United States, the European Union, Britain and Brazil — all upper-middle- or high-income countries — account for one-eighth of the world’s population but nearly half of all reported deaths. The U.S. alone has recorded over 740,000 lives lost, more than any other nation.

“This is a defining moment in our lifetime,” said Dr. Albert Ko, an infectious disease specialist at the Yale School of Public Health. “What do we have to do to protect ourselves so we don’t get to another 5 million?”

The death toll, as tallied by Johns Hopkins University, is about equal to the populations of Los Angeles and San Francisco combined. It rivals the number of people killed in battles among nations since 1950, according to estimates from the Peace Research Institute Oslo. Globally, COVID-19 is now the third leading cause of death, after heart disease and stroke.

The staggering figure is almost certainly an undercount because of limited testing and people dying at home without medical attention, especially in poor parts of the world, such as India.

Hot spots have shifted over the 22 months since the outbreak began, turning different places on the world map red. Now,&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-business-europe-pandemics-moscow-b844be49c2811a454440d4e84d5e5338">the virus is pummeling Russia</a>,&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-health-religion-europe-eastern-europe-2c9668cdc75b37ed140345405fcc3f54">Ukraine and other parts of Eastern Europe</a>, especially where rumors, misinformation and distrust in government have hobbled vaccination efforts. In Ukraine, only 17% of the adult population is fully vaccinated; in Armenia, only 7%.

“What’s uniquely different about this pandemic is it hit hardest the high-resource countries,” said Dr. Wafaa El-Sadr, director of ICAP, a global health center at Columbia University. “That’s the irony of COVID-19.”

Wealthier nations with longer life expectancies have larger proportions of older people, cancer survivors and nursing home residents, all of whom are especially vulnerable to COVID-19, El-Sadr noted. Poorer countries tend to have larger shares of children, teens and young adults, who are less likely to fall seriously ill from the coronavirus.

India, despite its terrifying delta surge that peaked in early May, now has a much lower reported daily death rate than wealthier Russia, the U.S. or Britain, though there is uncertainty around its figures.

The seeming disconnect between wealth and health is a paradox that disease experts will be pondering for years. But the pattern that is seen on the grand scale, when nations are compared, is different when examined at closer range. Within each wealthy country, when deaths and infections are mapped, poorer neighborhoods are hit hardest.

In the U.S., for example, COVID-19 has taken an outsize toll on Black and Hispanic people, who are more likely than white people to live in poverty and have less access to health care.

“When we get out our microscopes, we see that within countries, the most vulnerable have suffered most,” Ko said.

Wealth has also played a role in the global vaccination drive, with rich countries accused of locking up supplies. The U.S. and others are already dispensing booster shots at a time when millions&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-technology-business-cape-town-health-48046e5255cc3e4fa27455fc12ab5e52">across Africa haven’t received a single dose</a>, though the rich countries are also shipping hundreds of millions of shots to the rest of the world.

Africa remains the world’s&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-business-lifestyle-europe-philanthropy-31fd688936caec29ff082412ef23e30a">least vaccinated region</a>, with just 5% of the population of 1.3 billion people fully covered.

In Kampala, Uganda, Cissy Kagaba lost her 62-year-old mother on Christmas Day and her 76-year-old father days later.

“Christmas will never be the same for me,” said Kagaba, an anti-corruption activist in the East African country that has been through multiple lockdowns against the virus and where a curfew remains in place.

The pandemic has united the globe in grief and pushed survivors to the breaking point.

“Who else is there now? The responsibility is on me. COVID has changed my life,” said 32-year-old Reena Kesarwani, a mother of two boys, who was left to manage her late husband’s modest hardware store in a village in India.

Her husband, Anand Babu Kesarwani, died at 38 during India’s crushing coronavirus surge earlier this year. It overwhelmed one of the most chronically underfunded public health systems in the world and killed tens of thousands as hospitals ran out of oxygen and medicine.

In Bergamo, Italy, once the site of the West’s first deadly wave, 51-year-old Fabrizio Fidanza was deprived of a final farewell as his 86-year-old father lay dying in the hospital. He is still trying to come to terms with the loss more than a year later.

“For the last month, I never saw him,” Fidanza said during a visit to his father’s grave. “It was the worst moment. But coming here every week, helps me.”

Today, 92% of Bergamo’s eligible population have had at least one shot, the highest vaccination rate in Italy. The chief of medicine at Pope John XXIII Hospital, Dr. Stefano Fagiuoli, said he believes that’s a clear result of the city’s collective trauma, when the wail of ambulances was constant.

In Lake City, Florida, LaTasha Graham, 38, still gets mail almost daily for her 17-year-old daughter, Jo’Keria, who died of COVID-19 in August, days before starting her senior year of high school. The teen, who was buried in her cap and gown, wanted to be a trauma surgeon.

“I know that she would have made it. I know that she would have been where she wanted to go,” her mother said.

In Rio de Janeiro, Erika Machado scanned the list of names engraved on a long, undulating sculpture of oxidized steel that stands in Penitencia cemetery as an homage to some of Brazil’s COVID-19 victims. Then she found him: Wagner Machado, her father.

“My dad was the love of my life, my best friend,” said Machado, 40, a saleswoman who traveled from Sao Paulo to see her father’s name. “He was everything to me.”

By CARLA K. JOHNSON, Associated PressThe&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-five-million-dead-memorials-acd5a25aabb50f203c8ee059803a1bec">global death toll</a>&nbsp;from COVID-19 topped 5 million on Monday, less than two years into a crisis that has not only devastated poor countries but also humbled wealthy ones with first-rate health care systems.Together, the United States, the European Union, Britain and Brazil — all upper-middle- or high-income countries — account for one-eighth of the world’s population but nearly half of all reported deaths. The U.S. alone has recorded over 740,000 lives lost, more than any other nation.“This is a defining moment in our lifetime,” said Dr. Albert Ko, an infectious disease specialist at the Yale School of Public Health. “What do we have to do to protect ourselves so we don’t get to another 5 million?”The death toll, as tallied by Johns Hopkins University, is about equal to the populations of Los Angeles and San Francisco combined. It rivals the number of people killed in battles among nations since 1950, according to estimates from the Peace Research Institute Oslo. Globally, COVID-19 is now the third leading cause of death, after heart disease and stroke.The staggering figure is almost certainly an undercount because of limited testing and people dying at home without medical attention, especially in poor parts of the world, such as India.Hot spots have shifted over the 22 months since the outbreak began, turning different places on the world map red. Now,&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-business-europe-pandemics-moscow-b844be49c2811a454440d4e84d5e5338">the virus is pummeling Russia</a>,&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-health-religion-europe-eastern-europe-2c9668cdc75b37ed140345405fcc3f54">Ukraine and other parts of Eastern Europe</a>, especially where rumors, misinformation and distrust in government have hobbled vaccination efforts. In Ukraine, only 17% of the adult population is fully vaccinated; in Armenia, only 7%.“What’s uniquely different about this pandemic is it hit hardest the high-resource countries,” said Dr. Wafaa El-Sadr, director of ICAP, a global health center at Columbia University. “That’s the irony of COVID-19.”Wealthier nations with longer life expectancies have larger proportions of older people, cancer survivors and nursing home residents, all of whom are especially vulnerable to COVID-19, El-Sadr noted. Poorer countries tend to have larger shares of children, teens and young adults, who are less likely to fall seriously ill from the coronavirus.India, despite its terrifying delta surge that peaked in early May, now has a much lower reported daily death rate than wealthier Russia, the U.S. or Britain, though there is uncertainty around its figures.The seeming disconnect between wealth and health is a paradox that disease experts will be pondering for years. But the pattern that is seen on the grand scale, when nations are compared, is different when examined at closer range. Within each wealthy country, when deaths and infections are mapped, poorer neighborhoods are hit hardest.In the U.S., for example, COVID-19 has taken an outsize toll on Black and Hispanic people, who are more likely than white people to live in poverty and have less access to health care.“When we get out our microscopes, we see that within countries, the most vulnerable have suffered most,” Ko said.Wealth has also played a role in the global vaccination drive, with rich countries accused of locking up supplies. The U.S. and others are already dispensing booster shots at a time when millions&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-technology-business-cape-town-health-48046e5255cc3e4fa27455fc12ab5e52">across Africa haven’t received a single dose</a>, though the rich countries are also shipping hundreds of millions of shots to the rest of the world.Africa remains the world’s&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-business-lifestyle-europe-philanthropy-31fd688936caec29ff082412ef23e30a">least vaccinated region</a>, with just 5% of the population of 1.3 billion people fully covered.In Kampala, Uganda, Cissy Kagaba lost her 62-year-old mother on Christmas Day and her 76-year-old father days later.“Christmas will never be the same for me,” said Kagaba, an anti-corruption activist in the East African country that has been through multiple lockdowns against the virus and where a curfew remains in place.The pandemic has united the globe in grief and pushed survivors to the breaking point.“Who else is there now? The responsibility is on me. COVID has changed my life,” said 32-year-old Reena Kesarwani, a mother of two boys, who was left to manage her late husband’s modest hardware store in a village in India.Her husband, Anand Babu Kesarwani, died at 38 during India’s crushing coronavirus surge earlier this year. It overwhelmed one of the most chronically underfunded public health systems in the world and killed tens of thousands as hospitals ran out of oxygen and medicine.In Bergamo, Italy, once the site of the West’s first deadly wave, 51-year-old Fabrizio Fidanza was deprived of a final farewell as his 86-year-old father lay dying in the hospital. He is still trying to come to terms with the loss more than a year later.“For the last month, I never saw him,” Fidanza said during a visit to his father’s grave. “It was the worst moment. But coming here every week, helps me.”Today, 92% of Bergamo’s eligible population have had at least one shot, the highest vaccination rate in Italy. The chief of medicine at Pope John XXIII Hospital, Dr. Stefano Fagiuoli, said he believes that’s a clear result of the city’s collective trauma, when the wail of ambulances was constant.In Lake City, Florida, LaTasha Graham, 38, still gets mail almost daily for her 17-year-old daughter, Jo’Keria, who died of COVID-19 in August, days before starting her senior year of high school. The teen, who was buried in her cap and gown, wanted to be a trauma surgeon.“I know that she would have made it. I know that she would have been where she wanted to go,” her mother said.In Rio de Janeiro, Erika Machado scanned the list of names engraved on a long, undulating sculpture of oxidized steel that stands in Penitencia cemetery as an homage to some of Brazil’s COVID-19 victims. Then she found him: Wagner Machado, her father.“My dad was the love of my life, my best friend,” said Machado, 40, a saleswoman who traveled from Sao Paulo to see her father’s name. “He was everything to me.”___

COVID-19's global death toll tops 5 million 

WASHINGTON (AP) — Millions more Americans can get a COVID-19 booster and choose a different company’s vaccine for that next shot, federal health officials said Thursday.

Certain people who received Pfizer vaccinations months ago already are eligible for a booster and now the Centers for Disease Control and Prevention says specific Moderna and Johnson &amp; Johnson recipients qualify, too. And in a bigger change, the agency is allowing the flexibility of “mixing and matching” that extra dose regardless of which type people received first.

The Food and Drug Administration had already authorized such an expansion of the nation’s booster campaign on Wednesday, and it was also endorsed Thursday by a CDC advisory panel. CDC Director Dr. Rochelle Walensky had the final word on who gets the extra doses.

“These past 20 months have taught us many things, but mostly to have humility,” she told the panel. “We are constantly learning about this virus, growing the evidence base and accumulating more data.”

There still are restrictions on who qualifies and when for a booster. Starting six months past their last Pfizer or Moderna vaccination, people are urged to get a booster if they’re 65 or older, nursing home residents, or at least 50 and at increased risk of severe disease because of health problems. Boosters also were allowed, but not urged, for adults of any age at increased risk of infection because of health problems or their jobs or living conditions. That includes health care workers, teachers and people in jails or homeless shelters.

Moderna’s booster will come at half the dose of the original two shots.

As for recipients of the single-shot J&amp;J vaccine, a COVID-19 booster is recommended for everyone at least two months after their vaccination. That’s because the J&amp;J vaccine hasn’t proved as protective as the two-dose Moderna or Pfizer options.

The CDC panel didn’t explicitly recommend anyone get a different brand than they started with but left open the option — saying only that a booster of some sort was recommended. And some of the advisers said they would prefer that J&amp;J recipients receive a competitor’s booster, citing preliminary data from an ongoing government study that suggested a bigger boost in virus-fighting antibodies from that combination.

“We’re at a different place in the pandemic than we were earlier” when supply constraints meant people had to take whatever shot they were offered, noted CDC adviser Dr. Helen Keipp Talbot of Vanderbilt University.

She called it “priceless” to be able to choose a different kind for the booster if, for example, someone might be at risk for a rare side effect from a specific vaccine.

About two-thirds of Americans eligible for COVID-19 shots are fully vaccinated, and the government says getting first shots to the unvaccinated remain the priority. While health authorities hope boosters will shore up waning immunity against milder coronavirus infections, all the vaccines still offer strong protection against hospitalizations and death, even as the extra-contagious delta variant burned through the country.

And CDC’s advisers wrestled with whether people who didn’t really need boosters might be getting them, especially young, otherwise healthy adults whose only qualification was their job.

Dr. Sarah Long of Drexel University voiced concerns about opening those people to rare but serious side effects from another dose if they already were adequately protected.

“I have my own concerns that we appear to be recommending vaccines for people who I don’t think need it,” added Dr. Beth Bell of the University of Washington.

But she stressed that the vaccines work and that moving forward with the recommendations makes sense for the sake of being clear and allowing flexibility when it comes to boosters.

Despite the concerns by some members, the panels’ votes ended up being unanimous.

The vast majority of the nearly 190 million Americans who are fully vaccinated against COVID-19 have received the Pfizer or Moderna options, while J&amp;J recipients account for only about 15 million.

<figure>
 <img src="https://media.eaglewebservices.com/public/2021/10/1634854349255.png" alt="CDC Director Dr. Rochelle Walensky had the final word on who gets the extra doses." />
 <figcaption>CDC Director Dr. Rochelle Walensky had the final word on who gets the extra doses.</figcaption>
 </figure>WASHINGTON (AP) — Millions more Americans can get a COVID-19 booster and choose a different company’s vaccine for that next shot, federal health officials said Thursday.<div><iframe width="560" height="315" src="https://www.youtube.com/embed/Qoqia5YkwHc?start=24501" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe></div>Certain people who received Pfizer vaccinations months ago already are eligible for a booster and now the Centers for Disease Control and Prevention says specific Moderna and Johnson &amp; Johnson recipients qualify, too. And in a bigger change, the agency is allowing the flexibility of “mixing and matching” that extra dose regardless of which type people received first.The Food and Drug Administration had already authorized such an expansion of the nation’s booster campaign on Wednesday, and it was also endorsed Thursday by a CDC advisory panel. CDC Director Dr. Rochelle Walensky had the final word on who gets the extra doses.“These past 20 months have taught us many things, but mostly to have humility,” she told the panel. “We are constantly learning about this virus, growing the evidence base and accumulating more data.”There still are restrictions on who qualifies and when for a booster. Starting six months past their last Pfizer or Moderna vaccination, people are urged to get a booster if they’re 65 or older, nursing home residents, or at least 50 and at increased risk of severe disease because of health problems. Boosters also were allowed, but not urged, for adults of any age at increased risk of infection because of health problems or their jobs or living conditions. That includes health care workers, teachers and people in jails or homeless shelters.Moderna’s booster will come at half the dose of the original two shots.As for recipients of the single-shot J&amp;J vaccine, a COVID-19 booster is recommended for everyone at least two months after their vaccination. That’s because the J&amp;J vaccine hasn’t proved as protective as the two-dose Moderna or Pfizer options.The CDC panel didn’t explicitly recommend anyone get a different brand than they started with but left open the option — saying only that a booster of some sort was recommended. And some of the advisers said they would prefer that J&amp;J recipients receive a competitor’s booster, citing preliminary data from an ongoing government study that suggested a bigger boost in virus-fighting antibodies from that combination.“We’re at a different place in the pandemic than we were earlier” when supply constraints meant people had to take whatever shot they were offered, noted CDC adviser Dr. Helen Keipp Talbot of Vanderbilt University.She called it “priceless” to be able to choose a different kind for the booster if, for example, someone might be at risk for a rare side effect from a specific vaccine.About two-thirds of Americans eligible for COVID-19 shots are fully vaccinated, and the government says getting first shots to the unvaccinated remain the priority. While health authorities hope boosters will shore up waning immunity against milder coronavirus infections, all the vaccines still offer strong protection against hospitalizations and death, even as the extra-contagious delta variant burned through the country.And CDC’s advisers wrestled with whether people who didn’t really need boosters might be getting them, especially young, otherwise healthy adults whose only qualification was their job.Dr. Sarah Long of Drexel University voiced concerns about opening those people to rare but serious side effects from another dose if they already were adequately protected.“I have my own concerns that we appear to be recommending vaccines for people who I don’t think need it,” added Dr. Beth Bell of the University of Washington.But she stressed that the vaccines work and that moving forward with the recommendations makes sense for the sake of being clear and allowing flexibility when it comes to boosters.Despite the concerns by some members, the panels’ votes ended up being unanimous.The vast majority of the nearly 190 million Americans who are fully vaccinated against COVID-19 have received the Pfizer or Moderna options, while J&amp;J recipients account for only about 15 million.___

🎥 COVID-19 vaccine: CDC panel backs expanded booster rollout

WASHINGTON (AP) — U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson &amp; Johnson vaccine and said anyone eligible for an extra dose can get a brand different from the one they received initially.

The Food and Drug Administration’s decisions mark a big step toward expanding the U.S. booster campaign, which began with extra doses of the Pfizer vaccine last month. But before more people roll up their sleeves, the Centers for Disease Control and Prevention will consult an expert panel Thursday before finalizing official recommendations for who should get boosters and when.

The latest moves would expand by tens of millions the number of Americans eligible for boosters and formally allow “mixing and matching” of shots — making it simpler to get another dose, especially for people who had a side effect from one brand but still want the proven protection of vaccination.

Specifically, the FDA authorized a third Moderna shot for seniors and others at high risk from COVID-19 because of their health problems, jobs or living conditions — six months after their last shot. One big change: Moderna’s booster will be half the dose that’s used for the first two shots, based on company data showing that was plenty to rev up immunity again.

For J&amp;J’s single-shot vaccine, the FDA said all U.S. recipients, no matter their age, could get a second dose at least two months following their initial vaccination.

WASHINGTON (AP) — U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson &amp; Johnson vaccine and said anyone eligible for an extra dose can get a brand different from the one they received initially.<div><iframe width="560" height="315" src="https://www.youtube.com/embed/rou7tf4vaUU?start=414" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe></div>The Food and Drug Administration’s decisions mark a big step toward expanding the U.S. booster campaign, which began with extra doses of the Pfizer vaccine last month. But before more people roll up their sleeves, the Centers for Disease Control and Prevention will consult an expert panel Thursday before finalizing official recommendations for who should get boosters and when.The latest moves would expand by tens of millions the number of Americans eligible for boosters and formally allow “mixing and matching” of shots — making it simpler to get another dose, especially for people who had a side effect from one brand but still want the proven protection of vaccination.Specifically, the FDA authorized a third Moderna shot for seniors and others at high risk from COVID-19 because of their health problems, jobs or living conditions — six months after their last shot. One big change: Moderna’s booster will be half the dose that’s used for the first two shots, based on company data showing that was plenty to rev up immunity again.For J&amp;J’s single-shot vaccine, the FDA said all U.S. recipients, no matter their age, could get a second dose at least two months following their initial vaccination.The FDA rulings differ because the vaccines are made differently, with different dosing schedules — and the J&amp;J vaccine has consistently shown a lower level of effectiveness than either of the two-shot Moderna and Pfizer vaccines.As for mixing and matching, the FDA said it’s OK to use any brand for the booster regardless of which vaccination people got first. The interchangeability of the shots is expected to speed the booster campaign, particularly in nursing homes and other institutional settings where residents have received different shots over time.FDA’s acting commissioner Dr. Janet Woodcock said the agency wanted to make its booster guidance as flexible as possible, given that many people don’t remember which brand they first received. In other cases, some people may want to try a different vaccine if they previously experienced common side effects like muscle ache or chills.Still, regulators said it’s likely many people will stick with the same vaccine brand.The decision was based on preliminary results from a government study of different booster combinations that showed an extra dose of any type revs up levels of virus-fighting antibodies. That study also showed recipients of the single-dose J&amp;J vaccination had a far bigger response if they got a full-strength Moderna booster or a Pfizer booster rather than a second J&amp;J shot. The study didn’t test the half-dose Moderna booster.Health authorities stress that the priority still is getting first shots to about 65 million eligible Americans who remain unvaccinated. But the booster campaign is meant to shore up protection against the virus amid signs that vaccine effectiveness is waning against mild infections, even though all three brands continue to protect against hospitalization and death.“Today the currently available data suggest waning immunity in some populations of fully vaccinated people,” Woodcock told reporters. “The availability of these authorized boosters is important for continued protection against COVID-19 disease.”The Moderna booster decision essentially matches FDA’s ruling that high-risk groups are eligible for the Pfizer vaccine, which is made with the same technology.FDA recommended that everyone who’d gotten the single-shot J&amp;J vaccine get a booster since it has consistently shown lower protection than its two-shot rivals. And several independent FDA advisers who backed the booster decision suggested J&amp;J’s vaccine should have originally been designed to require two doses.Experts continue to debate the rationale of the booster campaign. Some warn that the U.S. government hasn’t clearly articulated the goals of boosters given that the shots continue to head off the worst effects of COVID-19, and wonder if the aim is to tamp down on virus spread by curbing, at least temporarily, milder infections.FDA’s top vaccine official suggested regulators would move quickly to expand boosters to lower age groups, such as people in their 40s and 50s, if warranted.“We are watching this very closely and will take action as appropriate to make sure that the maximum protection is provided to the population,” said FDA’s Dr. Peter Marks.In August, the Biden administration announced plans for an across-the-board booster campaign aimed at all U.S. adults, but outside experts have repeatedly argued against such a sweeping effort.On Thursday an influential panel convened by the CDC is expected to offer more specifics on who should get boosters and when. Their recommendations are subject to approval by the CDC director.The vast majority of the nearly 190 million Americans who are fully vaccinated against COVID-19 have received the Pfizer or Moderna options, while about 15 million have received the J&amp;J vaccine.___

Coronavirus Update